Sprycel Approval History

• FDA approved: Yes (First approved June 28th, 2006)
• Brand name: Sprycel
• Generic name: dasatinib
• Company: Bristol-Myers Squibb Company
• Treatment for: Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia

Sprycel (dasatinib) is a kinase inhibitor indicated for the treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

FDA Approval History for Sprycel

Date	Article
Oct 28, 2010	FDA approves additional medical indication for Sprycel
May 26, 2009	FDA Grants Full Approval for Sprycel (dasatinib) for the Treatment of Adults with Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Prior Therapies Including Gleevec
Nov  9, 2007	FDA Approves New Sprycel (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Jun 28, 2006	Sprycel Bristol-Myers Squibb Company - Treatment for Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)
Jun  2, 2006	Bristol-Myers Squibb Issues Statement on Oncologic Drugs Advisory Committee Vote in Favor of Investigational Drug Dasatinib
Mar  7, 2006	FDA Grants Priority Review for Bristol-Myers Squibb's Investigational Oncology Treatment Dasatinib
Dec 28, 2005	Bristol-Myers Squibb Submits New Drug Application for Dasatinib

See also...

Sprycel (dasatinib) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.